Glycogen synthase kinase-3β: A multifaceted player in ischemia-reperfusion injury and its therapeutic prospects.

Autor: Li J; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Zhang Y; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Tang R; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Liu H; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Li X; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Lei W; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Chen J; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Jin Z; Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, China., Tang J; Department of Cardiovascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, China., Wang Z; Department of Cardiothoracic Surgery, Central Theater Command General Hospital of Chinese People's Liberation Army, Wuhan, China., Yang Y; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China., Wu X; Xi'an Key Laboratory of Innovative Drug Research for Heart Failure, Northwest University First Hospital, Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.; Faculty of Life Sciences and Medicine, Northwest University, Xi'an, China.
Jazyk: angličtina
Zdroj: Journal of cellular physiology [J Cell Physiol] 2024 Sep; Vol. 239 (9), pp. e31335. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1002/jcp.31335
Abstrakt: Ischemia-reperfusion injury (IRI) results in irreversible metabolic dysfunction and structural damage to tissues or organs, posing a formidable challenge in the field of organ implantation, cardiothoracic surgery, and general surgery. Glycogen synthase kinase-3β (GSK-3β) a multifunctional serine/threonine kinase, is involved in a variety of biological processes, including cell proliferation, apoptosis, and immune response. Phosphorylation of its tyrosine 216 and serine 9 sites positively and negatively regulates the activation and inactivation of the enzyme. Significantly, inhibition or inactivation of GSK-3β provides protection against IRI, making it a viable target for drug development. Though numerous GSK-3β inhibitors have been identified to date, the development of therapeutic treatments remains a considerable distance away. In light of this, this review summarizes the complicated network of GSK-3β roles in IRI. First, we provide an overview of GSK-3β's basic background. Subsequently, we briefly review the pathological mechanisms of GSK-3β in accelerating IRI, and highlight the latest progress of GSK-3β in multiorgan IRI, encompassing heart, brain, kidney, liver, and intestine. Finally, we discuss the current development of GSK-3β inhibitors in various organ IRI, offering a thorough and insightful reference for GSK-3β as a potential target for future IRI therapy.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: